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Abstract
Despite a relative contraindication, mechanical support with Impella™ left ventricular assist device has already been described
for ischaemic ventricular septal defect treatment, either as a bridge to surgery, as intraoperative mechanical haemodynamic
support, or to ensure intraprocedural haemodynamic stability during device closure. We describe two cases of ventricular sep-
tal defect complicating acute myocardial infarction, where the percutaneous ImpellaCP was implanted early (differently than
previously described) with the aim of preventing haemodynamic instability, while deferring surgical repair. We present a re-
port of haemodynamic, echocardiographic, biochemical, and clinical data of two consecutive cases of ImpellaCP use, within
a minimally invasive monitoring and therapeutic approach. In two cases of subacute myocardial infarction-related ventricular
septal defect not amenable to percutaneous device closure, the use ImpellaCP was successful: it was followed by effective and
rapid right and left ventricular unloading, by major haemodynamic instability prevention and protection from systemic venous
congestion, from kidney and splanchnic organ failures. This allowed bridging to appropriately timed surgical repair. These cases
suggest a potentially effective, clinically grounded strategy in the early management of ischaemic ventricular septal defect pa-
tients, with the aim of deferring surgery beyond the safer 7 days cutoff associated with a lower perioperative mortality.
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Introduction
Acute myocardial infarction (AMI) complicated by ventricular
septal defect (VSD) is a life-threatening, rare complication
(0.2–3%) of all AMIs,1,2 burdened by an extremely high mor-
tality (41–80%).2 The urgency of defect closure conflicts with
poor outcome due to surgery performed on a fragile, recently
infarcted, myocardial tissue.3 Perioperative traditional VSD
management entails catecholamine infusion4 and aortic
counterpulsation. Recently, forms of mechanical haemody-
namic support have been proposed.5,6
Although VSD is described as relative contraindication for
the left ventricular (LV) coaxial heart pump Impella, its use
has already been reported, so far in only nine patients, as
an LV assist device to bridge to surgery in shocked/post-
cardiac arrest patients7,8 to ensure intraprocedural haemo-
dynamic stability during device closure9 and, intraopera-
tively, as a right ventricular assist device to aid weaning
from extracorporeal circulation.10,11 A very small case series
indeed was weighed by high mortality when Impella was
used in the context of advanced haemodynamic impair-
ment. Besides intraprocedural applications, where
Impella2.5™ (maximum 2.5 L/min flow, percutaneous ac-
cess) was implanted, all other applications in the setting
of VSD described a use of Impella5.0™ (max 5.0 L/min flow,
surgical, axillary insertion).
In a recent computer simulation model, Impella was shown
to effectively reduce both left-to-right shunt and LV filling
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Figure 1 (A) Case 1: modified transthoracic echocardiography (TTE) parasternal long axis view showing mid-distal anterior ventricular septal defect
(VSD, arrow). (B) Case 1: same TTE view, with left-to-right shunt portrayed as high-speed turbulent color jet through the VSD. (C) Case 1: apical 4 cham-




. (D) Case 1: TTE subcostal in-
ferior vena cava (IVC) view showing a dilated IVC (end expiratory diameter 22 mm). Inspiratory IVC size reduction was also measured as being 5%. (E)
Case 1: same view as in panel C, immediately after ImpellaCP left ventricular assist device implant. RV size significantly reduced (measured RV indexed




. (F) Case 1: same view as in panel D, immediately after left ventricular assist device implant. IVC end expiratory size
significantly reduced to a size of 17 mm. IVC size inspiratory reduction also improved, becoming equal to 20%. (G) Case 2: TTE subcostal long axis view
showing a basal inferoseptal VSD (arrow). (H) Case 2: TTE parasternal basal short axis view, showing a high flow turbulent left-to-right color flow
through the inferobasal VSD.
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pressures in AMI-VSD, resulting as the optimal haemody-
namic support.12
Case reports
We describe two cases of acute ischaemic VSD in which the
percutaneous ImpellaCP™ (AbioMed Inc., Danvers, Massachu-
setts, USA; 3.8 L/min maximum flow, percutaneous insertion)
was early implanted, in conditions of haemodynamic stability,
to prevent cardiovascular deterioration and allow surgical re-
pair delay to a safer time frame.
Patient 1
A 76-year-old woman with no antecedent medical history
was admitted to the hospital because of worsening fatigue
and dyspnoea for 5 days. Electrocardiogram (ECG) showed
V1–V4 and D1 ST elevation and V3–V4 Q wave, consistent
with subacute anterior ST-elevation myocardial infarction
(STEMI). Troponin T at admission (hTnT) was 255 ng/mL.
Echocardiography revealed a LV ejection fraction of 52%,
(with apical and mid-anteroseptal akinesia, mid-anterior and
basal anteroseptal hypokinesia), a dilated and hypokinetic
right ventricle (RV) [indexed end-diastolic area 13.4 cm2/m2,
tricuspid annular plane systolic excursion (TAPSE) 10 mm,
fractional area change (FAC) 26%], and an estimated systolic
pulmonary artery pressure of 45 mmHg. Further, a mid-distal
anterior VSD (15 × 15 mm size), with significant left-to-right
shunt flow, and caval plethora [inferior vena cava (IVC),
22 mm diameter, 5% inspiratory collapsibility) were found.
(Figure 1 and Table 1)
Haemodynamic and respiratory parameters were stable at
intensive care unit (ICU) admission (blood pressure 142/107/
90 mmHg, synus rhythm 105 b.p.m., lactates 1.4 mMol/L,
SvCO2 76%, SpO2 97% with O2 2 L/min). ImpellaCP was im-
planted, and flow rate was maintained at 2.5–2.8 L/min
(P6–P8). One hour after ImpellaCP implant, RV and IVC sizes
reduced (indexed end-diastolic area 10.6 cm2/m2, IVC diame-
ter 17 mm, 20% collapsibility), RV function improved (TAPSE
15 mm, FAC 32%), and central venous pressure (CVP) de-
creased (from 13 to 8 mmHg) (Figure 1 and Table 1). Coro-
nary angiography revealed an occluded left anterior
descending artery that was left untreated because of the 5-
day delay from symptoms onset, the absence of ECG signs
of ongoing ischaemia, and the presence of an evident ne-
crotic corresponding myocardium.4 hTnT peaked on Day 1
(327 mcg/L), consistently with the evolution of a non-
reperfused subacute STEMI. ImpellaCP was kept for 8 days.
During this period, haemodynamics remained stable with no
need of inotropes nor mechanical ventilation. N terminal
proBNP (NT-proBNP) level decreased from 12 275 (before
ImpellaCP) to 10 840 (first day after ImpellaCP) and to 7303
pg/mL (fifth day after ImpellaCP); renal and hepatic functions
were preserved (Supporting Information, Table S1). No signs
of major neurological dysfunction were observed. Surgical re-
pair with pericardial patch and ventriculoplasty were per-
formed successfully on Day 8. She was discharged from the
ICU on post-operative day (POD) 3 and from hospital on
POD 10. The 6-month follow-up was recorded free of further
events, with a New York Heart Association class I, normal he-
patic and renal function tests, and a functional capacity corre-
sponding to >4 metabolic equivalents of task.
Patient 2
An 86-year-old man with previous recurrent pulmonary em-
bolism (last episode was 30 years before, currently under oral
anticoagulants) presented to the emergency department
Table 1 Cardiovascular and echocardiographic parameters before and after ImpellaCP left ventricular assist device implant, demonstrat-
ing right ventricular overload reduction
CASE 1 CASE 2
PRE POST PRE POST
SAPm (mmHg) 107 89 88 76
CVP (mmHg) 13 8 17 9





) 13.4 10.6 17.8 15.3
TAPSE (mm) 10 15 7 10
RV FAC (%) 26 32 10 18
IVC (mm) 22 17 28 27
IVCc (%) 5 20 7 18
SpO2 (%) 97 100 95 98
SVcO2 (%) 76 80 50 67
CVP, central venous pressure; FAC, fractional area change; HR, heart rate; IVC, inferior vena cava; IVCc, IVC collapsibility index; iRVEDA,
indexed right ventricular end-diastolic area; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; SAPm, mean systemic
arterial pressure; SVcO2, central venous oxygen saturation.
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with dyspnoea and relapsing retrosternal typical pain for 4
days. ECG showed V2–V3 ST depression, DII, DIII, aVF ST ele-
vation and Q waves, consistent with subacute inferior AMI.
hTnT at admission was 1085 ng/mL. Echocardiography re-
vealed mid-basal inferior and inferoseptal akinesia, ejection
fraction > 60%, a dilated and hypokinetic RV (apical 4 cham-
ber indexed end-diastolic area 17.8 cm2/m2, TAPSE 7 mm,
FAC 10%), estimated systolic pulmonary artery pressure 40
mmHg, and a basal inferoseptal VSD (20 × 15 mm size) with
relevant left-to-right shunt flow, caval plethora (IVC 28 mm,
7% inspiratory collapsibility) (Table 1).
Haemodynamic and respiratory parameters were relatively
stable at ICU admission (blood pressure 123/88/70, heart
rate 87sinus, lactates 1.79 mMol/L, SvCO2 50%, SpO2 95%
with O2 3 L/min). ImpellaCP was then implanted percutane-
ously, and flow rate maintained at 3-3.4 L/min (P8). One hour
after ImpellaCP implant, RV and IVC sizes reduced (indexed
end-diastolic area 15.3 cm2/m2, IVC size 27 mm, 18% collaps-
ibility), RV function improved (TAPSE 10 mm, FAC 18%), and
CVP decreased (from 17 to 9 mmHg). Low dose dobutamine
(3 mcg/kg/min) was then started, and RV systolic function
further improved (TAPSE 13 mm, FAC 20%); SVcO2 also in-
creased to 67% (Table 1).
Coronary angiography showed 100% occlusion of the mid-
right coronary artery as culprit vessel, which was not treated,
because of the subacute nature of AMI and absent ECG left
and right signs of ongoing ischaemia.4 hTnT peaked on Day
1 (1438 mcg/L). ImpellaCP was kept for 7 days. The patient
did not require mechanical ventilation. The NT-proBNP level
decreased from 27 072 (before ImpellaCP) to 9127 (first day
after ImpellaCP) and 8020 pg/mL (fifth day after ImpellaCP);
renal and liver function improved along with improvement
of RV function (Supporting Information, Table S1). Neurolog-
ical course was uneventful. Surgical VSD pericardial patch re-
pair was uneventfully performed 7 days later. The patient
was discharged from ICU on POD 12 and from hospital at
POD 30, following respiratory and physical rehabilitation. At
6 months, he is still alive, with normal hepatic and renal func-
tion tests, New York Heart Association class III and a func-
tional capacity corresponding to <4 metabolic equivalents
of task.
Discussion
ImpellaCP is currently indicated for both elective and emer-
gent high-risk percutaneous coronary interventions in the
setting of LV dysfunction. It has also been adopted for LV
unloading in STEMI patients without cardiogenic shock prior
to percutaneous reperfusion, to reduce the ischaemia reper-
fusion injury and overall myocardial damage by myocardial
preconditioning.13
We herein report for the first time a novel early use of
ImpellaCP (before haemodynamic decompensation) in post-
AMI VSD patients. Selection criteria of the two patients for
this short-term percutaneous mechanical support were age
> 75 years, unfavourable septal anatomy for device place-
ment, and absence of severe peripheral vascular disease, a
mechanical aortic valve, more-than-mild aortic stenosis, and
LV mural thrombi. In both cases, VSD location and/or rim
were not amenable to percutaneous device therapy.14 The
goal was to unload the LV and the RV and to safely defer sur-
gery in order to allow for myocardial recovery and for stabili-
zation of the infarcted, ruptured tissue. The immediate
clinical, haemodynamic and echocardiographic improvement
upon ImpellaCP implantation suggests that this early mechan-
ical support significantly contributed to postpone surgery to
the optimal time frame, protecting the patients from the risk
of cardiovascular deterioration and venous congestion. Echo-
cardiography showed rapid RV size and IVC size reduction,
consistent with RV effective unloading. Patient 2 also re-
quired inotropic support (low dose and short term, according
to current guidelines15) to achieve a satisfactory optimization,
possibly due to preexistence of RV systolic dysfunction. In
both cases, the NT-proBNP reduction and absence of liver
and kidney function deterioration confirmed the reduction
in systemic venous congestion.
The overall approach was conducted by minimizing inva-
sive interventions. Daily transthoracic echocardiography
allowed adequate monitoring of cardiac function and
ImpellaCP correct position and function. The placement of
ImpellaCP requires no surgery, and the patients were not
intubated, nor developed subsequent respiratory or haemo-
dynamic deterioration requiring intubation. The absence of
haemodynamic deterioration waved the need of more inva-
sive cardiovascular monitoring than invasive blood pressure,
CVP, and indirect indices of global perfusion. Systemic
anticolagulation was effectively conducted with intravenous
non-fractioned heparin infusion (15.000–27.000 UI/day), to
prevent thrombosis of the Impella device. Sedation with
dexmedetomidine was necessary for Patient 1 due to an ep-
isode of delirium and for both to achieve sufficient safe main-
tenance of the device position. After Day 2, both patients
were enterally fed, with no side effects.
Of the so far reported cases of Impella use as bridge to sur-
gery in VSD,7,8 three patients out of six died, in the context of
multiple organ failure. Both of our patients in the cases of
early ImpellaCP implantation suffered no splanchnic organ
failure and survived, despite the older age (81 vs. 61.8 years
average age).
Left ventricular (and subsequently RV) unloading is a main-
stay of ischaemic VSD haemodynamic support.16 Although
Impella has not proven so far to be superior to intra-aortic
balloon pump (IABP) in improving short-term outcome in
post-AMI shock and in terms of cost effectiveness,17,18 its
pronounced LV unloading effect has been experimentally well
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demonstrated as reduction in LV end-diastolic volume, left
atrial volume, mean left atrial pressure and, differently from
IABP, preload.19 Moreover, Impella has also shown to effec-
tively reduce afterload, as compared with IABP, in patients
supported with veno-arterial extracorporeal membrane oxy-
genation (ECMO),20,21 the latter being in this context effec-
tive as percutaneous device for LV venting. Moreover,
Impella provides the advantage of combining this unloading
capability (greater than IABP, and potentially also than
veno-arterial ECMO in the face of very poor LV systolic func-
tion) with the generation of an antegrade flow (conversely to
peripheral veno-arterial ECMO retrograde flow; IABP can only
increase cardiac output by improving the heart’s native flow-
generating activity). Overall, the relative contraindication to
Impella use in VSD should be weighed in light of the
pros/cons of alternative strategies and of patient’s overall
clinical conditions and history. These cases suggest in fact a
potentially effective, clinically grounded strategy in the early
management of VSD patients. This may be particularly impor-
tant for VSD patients not amenable to more invasive forms of
mechanical support such as peripheral veno-arterial ECMO,
with the aim of deferring surgery beyond the safer 7 days
cutoff associated with a lower perioperative mortality.22 Fur-
ther investigations are warranted before this approach to be





Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Detailed clinical, biochemical, hemodynamic and
major outcome data of both patient 1 (top) and patient 2
(bottom).
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